secwatch.observer — SEC 8-K summary
======================================

Issuer:     CORCEPT THERAPEUTICS INC (CORT)
CIK:        0001088856
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001628280-22-028184
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corcept Q3 revenue $101.7M (+5.8% YoY); tightens 2022 guidance to $400-410M
---------------------------------------------------------------------------

- Diluted EPS $0.30 vs $0.24 in Q3 2021; net income $34.6M.
- Tightened FY 2022 revenue guidance to $400-410M from prior range.
- Cash and investments $401.2M at Sept 30, up from $382M at June 30.
- Operating expenses $69.8M (+16.5% YoY) on clinical and commercial expansion.
- Enrolling pivotal Phase 3 ROSELLA trial in ovarian cancer; GRATITUDE AIWG data expected Q4 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1088856/000162828022028184/0001628280-22-028184-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1088856/000162828022028184/cort-20221103.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-028184

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer